Biodexa Pharmaceuticals PLC announced that the U.S. Patent and Trademark Office allowed U.S. patent application No. 16/546,595 titled Prevention of Pancreatic Cell Degeneration which was exclusively licensed to Biodexa by Melior Pharmaceuticals Inc., along with other patents, in a transaction which closed in December 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | 0.00% | -24.24% | -62.69% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-62.69% | 4.38M | |
+2.93% | 108B | |
+8.82% | 105B | |
+2.10% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B |
- Stock Market
- Equities
- BDRX Stock
- News Biodexa Pharmaceuticals Plc
- Biodexa Pharmaceuticals Plc Announces Allowance of U.S. Patent Covering Tolimidone